Aria SVP Nonclinical R&D and Chemistry Anjali Pandey presents on the novel MOAs Aria has discovered for NASH shares preclinical results.

Aria SVP Nonclinical R&D and Chemistry Anjali Pandey presents on the novel MOAs Aria has discovered for NASH and IPF and shares preclinical results for both programs.

Aria VP of Discovery Aaron Daugherty presents on the fundamentals of drug discovery and Aria's Symphony platform.

Aria SVP Nonclinical R&D and Chemistry Anjali Pandey presents on the novel MOAs Aria has discovered for NASH and IPF and shares preclinical results for both programs.

Aria VP Discovery Aaron Daugherty will present on how Aria leverages AI for drug discovery, detailing how the platform reveals new biology to discover new therapies.

Aria Pharmaceuticals CEO Andrew Radin joins a panel to discuss how artificial intelligence has the potential to identify molecules and bring them to clinic faster.

Aria Pharmaceuticals CEO Andrew Radin joins a panel to discuss how artificial intelligence has been hailed as a game-changer in drug discovery for years—and now, it might actually be changing the game.

Aria Pharmaceuticals CEO Andrew Radin will be a featured speaker discussing the benefits and challenges of a fail fast strategy.

Aria Pharmaceuticals VP Discovery Aaron C Daugherty will be a featured speaker discussing how Aria leverages AI for drug discovery